Arrowhead Research Corporation (ARWR) Dividend History

Company News

• Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

  The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.

  GlobeNewswire Inc.

  Featured Companies: BBIO CRNX ETNB IONS NBIX
• NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling

  The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Zoom Video Communications The Trade: Zoom Video Communications, Inc. (NASDAQ: ZM) Director Santiago Subotovsky sold a total of 1,100 shares at an average price of $65.38. The insider received around $71,919 from selling those shares. What’s Happening: On March 26, Rosenblatt analyst Catharine Trebnick reiterated ...

  Benzinga

  Featured Companies: AFRM NTAP ZM
• EQT, Genie Energy And Other Big Stocks Moving Lower On Monday

  U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT) fell sharply during Monday’s session after the company announced that it entered into a definitive merger agreement to acquire Equitrans Midstream. EQT shares fell 8.4% to $34.37 on Monday. Here are some other big stocks recording losses in today’s session. Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares tumbled 18.5% to $8.09. Ventyx Biosciences reported clinical data for its NLRP3 inhibitor portfolio and issued pipeline updates at Virtual Investor Event. MoneyLion Inc. (NYSE: ML) dipped 15% to $63.36. Genie Energy Ltd. ...

  Benzinga

  Featured Companies: APLT ARQT BITF CLS CVNA EQT GNE MNKD PGY QSI SMCI VTYX
• Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

  U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE: COO) rose sharply during Friday’s session after the company reported better-than-expected first-quarter financial results and raised guidance. Cooper Companies posted adjusted earnings of 85 cents per share, beating market estimates of 78 cents per share. The company’s quarterly sales came in at $931.60 million versus expectations of $915.94 million, according to data from Benzinga Pro. The Cooper Companies shares rose 7.4% to $100.61 on Friday. Here are some other big stocks recording gains in today’s session. Dell Technologies Inc. (NYSE: DELL) jumped 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%. Sweetgreen, Inc. (NYSE: SG) rose 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results. Everbridge, Inc. (NASDAQ: EVBG) climbed 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo. NetApp, Inc. (NASDAQ:

  Benzinga

  Featured Companies: ARVN CLDX CLS COO CRNX DELL DYN MLTX MTZ NTAP PTCT RDNT RGNX RIG RMBS ROOT RPAY SANA SG SMCI TDW XPOF YMAB
• Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma

  Analysts' ratings for Arrowhead Pharma (NASDAQ:ARWR) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $42.17, a high estimate of $50.00, and a low estimate of $29.00. Surpassing the previous average price target of $34.50, the current average has increased by 22.23%. Interpreting Analyst Ratings: A Closer Look An in-depth analysis of recent analyst actions unveils how financial experts perceive Arrowhead Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Luca Issi RBC Capital Maintains Outperform $50.00 - Luca Issi RBC Capital Maintains Outperform $50.00 - Jason Gerberry B of A Securities Raises Buy $37.00 $29.00 Jason Gerberry B of A Securities Announces Buy $29.00 - Michael Ulz Morgan Stanley Lowers Equal-Weight $37.00 $40.00 Luca Issi RBC Capital Maintains Outperform $50.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ...Full story available on Benzinga.com

  Benzinga